ASIA PACIFIC ALOPECIA TREATMENT MARKET ANALYSIS

Market Challenges And Opportunities

Asia Pacific Alopecia Treatment Market– Drivers

Increasing Research and Development Activities in Alopecia Treatment

Increasing Research and development by key market players is expected to drive growth of Asia Pacific alopecia treatment market over the forecast period.  For instance, Aeterna Health on February 28, 2023 stated hair regrowth treatment combines traditional and cutting-edge technology, mainly adipose-derived cells, to provide the best results for our patients. The treatments have the ability to self-renew and differentiate into various types of cells, making them a potential therapy for promoting hair growth. Cell therapy involves extracting cells from a patient’s adipose tissue, then culturing these cells in a laboratory before injecting them into the patient’s scalp.These cells can stimulate hair follicle growth, promote hair growth cycles, and improve hair quality and density. This treatment method is more effective than traditional drug therapies as it can promote scalp blood circulation, increase hair follicle nutrient supply, and thereby promote healthy hair growth.

Figure 2. Asia Pacific Alopecia Treatment Market Share (%), By Country, 2023

Asia Pacific Alopecia Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others faced problems regarding transportation of drugs from one place to another.

COVID 19 had negative impact on the Asia Pacific alopecia treatment market.  For instance, an article published by National Center for Biotechnology Information on May 8, 2022 explained 57 patients participated in which the majority (84.2%) of the participants had mild anxiety assessed by corona disease anxiety scale. Two patients had got infected with COVID-19. Twenty-one participants experienced hair loss progression. Hair loss progression correlated with drug dose reduction although it did not influence by the level of anxiety evaluated by the  corona disease anxiety scale anxiety perceived by severe Alopecia Areata patients about COVID-19 is mild; however, many experience hair loss progressions owing to their drug dose reduction.

Asia Pacific Alopecia Treatment Market: Restraints

Side Effects of Alopecia Drugs

The side effects of alopecia drugs is expected to hamper the Asia Pacific alopecia treatment market growth. For instance, according to an article published by U.S Food and Drug Administration, on June 14, 2022, explained FDA-approved alopecia drug olumiant has side effects and have to conduct liver and kidney function tests apart from ruling out latent tuberculosis. Olumiant is an inhibitor that blocks the activity of one or more specific enzyme families, thus disrupting a pathway that leads to inflammation. Eli Lilly's drug baricitinib regrows hair by preventing the immune system from attacking the hair follicle. It treats the whole body, not a specific part. The efficacy and safety of the drug were tested in two randomized, placebo-controlled, double-blind studies in patients with at least 50 percent scalp hair loss.

To counterbalance this restraint, a robust protocol should be introduce to develop drugs with less side effects.